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Cancer gene discovery has relied extensively
on analyzing tumors for gains and losses to
reveal the location of oncogenes and tumor
suppressor genes, respectively. Deletions of
1p36 are extremely common genetic lesions in
human cancer, occurring in malignancies of
epithelial, neural, and hematopoietic origin. Al-
though this suggests that 1p36 harbors a gene
that drives tumorigenesis when inactivated,
the identity of this tumor suppressor has re-
mained elusive. Herewe use chromosome engi-
neering to generate mouse models with gain
and loss of a region corresponding to human
1p36. This approach functionally identifies
chromodomain helicase DNA binding domain
5 (Chd5) as a tumor suppressor that controls
proliferation, apoptosis, and senescence via the
p19Arf/p53 pathway.We demonstrate that Chd5
functions as a tumor suppressor in vivo and
implicate deletion of CHD5 in human cancer.
Identification of this tumor suppressor provides
new avenues for exploring innovative clinical
interventions for cancer.
INTRODUCTION
Identifying cancer genes and understanding how they
contribute to tumorigenesis are critical steps in controlling
cancer. Although progress has been made with onco-
genes, success has been limited with tumor suppressors.
Most tumor suppressor genes identified thus far were
found by using positional cloning of genes involved in hu-
man hereditary cancer syndromes, including retinoblas-
toma (Friend et al., 1987; Lee et al., 1987), Wilm’s tumor
(Call et al., 1990; Gessler et al., 1990), neurofibromatosis
type I (Cawthon et al., 1990; Wallace et al., 1990), colorec-
tal cancer (Fearon et al., 1990), and breast cancer (Mikiet al., 1994; Wooster et al., 1995). However, most cancers
involve spontaneous mutations; therefore, key tumor sup-
pressors have likely eluded detection using these classical
approaches.
More recently, systematic approaches to scan the
genome for chromosomal gains and losses have been
used to identify cancer genes. Since end-stage tumors
are typically used in these studies, a limitation of this ap-
proach is that a plethora of genomic alterations are usually
detected, making it difficult to identify events that initiate
the tumorigenic process.
Despite these challenges, analyses of sporadic cancers
have located commonly deleted regions, suggesting that
genes in these intervals encode proteins that protect
from malignancy. The short arm of human chromosome
1 (1p), for example, is frequently deleted in human cancer,
with 1p36 deletion being the most common lesion. 1p36
deletions were first reported in neuroblastoma in 1977
(Brodeur et al., 1977) and have since been confirmed by
others (White et al., 1995; White et al., 2005). Other neu-
ral-related malignancies associated with 1p36 deletions
include meningioma (Piaskowski et al., 2005), melanoma
(Poetsch et al., 2003), pheochromocytoma (Moley et al.,
1992), and oligodendroglioma (Bello et al., 1995). 1p36 is
also deleted in hematopoietic malignancies including
acute myelogenous leukemia (AML) (Mori et al., 2003),
chronic myelogenous leukemia (CML) (Mori et al., 1998),
and non-Hodgkin’s lymphoma (Melendez et al., 2003) as
well as in epithelial malignancies including those of the
thyroid (Kleer et al., 2000), colon (Praml et al., 1995), cervix
(Cheung et al., 2005), and breast (Bieche et al., 1993).
These data suggest that one or more tumor suppressor
genes mapping to 1p36 are lost or inactivated in a variety
of human cancers. Identifying the 1p36 tumor suppressor
and determining how its encoded protein suppresses ma-
lignancy may reveal an underlying molecular mechanism
that protects against diverse types of cancer. However,
the 1p36 tumor suppressor has remained elusive.
In this report, we identify a tumor suppressor mapping
to 1p36. By using chromosome engineering (Ramirez-
Solis et al., 1995) (reviewed in Mills and Bradley [2001]),Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 459
Figure 1. Engineering Rearrangements Corresponding to Human 1p36
(A) 1p36 corresponds to distal mouse chromosome 4 (hatched bars). The 4.3 Mb D4Mit190-Mit51 region is the focus of this study.
(B) Genes are shown in clusters I–IV (see Table S1 and Figure S1 for details).
(C) Gene targeting at D4Mit190 resulted in integration of a loxP site (triangle), a neomycin resistance cassette (N), the 50 half of the hprt locus (50), and
the Tyrosinase gene (Ty) at the endogenous (wild-type, wt) D4Mit190 locus (upper). Targeting was assessed by Southern analysis of NdeI
(Nd)-digested DNA fromG418-resistant (GR) clones by using the 1.5 kb HpaI gap probe; a 16.2 kb fragment is diagnostic for singly targeted (st) clones
(lower). E, endogenous; T, targeted alleles.460 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.
we established mouse strains with a gain and loss of a
genomic interval corresponding to human 1p36 and used
these models to identify a 4.3 Mb region that encodes
a potent regulator of proliferation, cellular senescence,
apoptosis, and tumorigenesis. We determined that Chd5
is the gene within this interval that functions as a tumor
suppressor and found that CHD5 is frequently deleted in
human cancer. These findings identify CHD5 as a novel
tumor suppressormapping to 1p36 and provide functional
evidence for its molecular mechanism in cancer.
RESULTS
Generation of Mouse Strains with Rearrangements
Corresponding to Human 1p36
To functionally identify novel tumor suppressor genes
mapping to human 1p36, we generated mouse strains
with deletions (also called deficiencies, df) or duplications
(dp) of this region. df heterozygous and dp heterozygous
mice have decreased and increased dosage of genes
mapping within the rearranged interval, respectively, and
therefore provide genetic models for functionally charac-
terizing genes mapping to human 1p36.
Mouse D4Mit190-D4Mit51 (D4Mit190-51) maps to hu-
man 1p36 (Figures 1A and 1B; see Figure S1 and Table
S1 in the Supplemental Data available with this article
online). df and dp alleles of this interval were generated
by using chromosome engineering in mouse embryonic
stem (ES) cells (Figures 1C–1E; Figure S2). Targeting at
D4Mit190 occurred with a frequency of 30.7%, and germ-
line competent clones were targeted at D4Mit51 with an
efficiency of 36.1% (Figures 1C and 1D). Eleven doubly
targeted clones were electroporated with a Cre-express-
ing construct, and clones were grown in media containing
HAT to select for rearrangements (Figure 1E; Figure S2B).
Drug selection revealed that four clones were df hetero-
zygous and seven were df/dp, indicating that targeting
had occurred in cis and trans, respectively (Figure 1E;
Figure S2B).
Two different df/dp clones were established as mouse
strains and offspring genotyped by PCR. Whereas df het-
erozygousmice (n = 41) were generated out of eight litters,
dp heterozygous weanling mice were not obtained, even
though the dp heterozygous allele should have been
transmitted to half of the Agouti progeny. When embryos
from similar crosses were harvested during late gestation,
however, df heterozygous (n = 22) and dp heterozygous
(n = 20) progeny were obtained (Figure 1F). These obser-
vations indicate that deficiency of D4Mit190-51 is toler-ated during embryonic development but that duplication
of this region causes perinatal lethality.
dp Heterozygous MEFs Have Decreased
Proliferation and Enhanced Senescence
To evaluate the cellular phenotype dp heterozygous mice,
mouse embryonic fibroblasts (MEFs) from 13.5 day em-
bryos (E13.5) from wild-type X df/dp matings were
assayed for proliferation (Figure 2A).While wild-typeMEFs
proliferated robustly, dp heterozygous MEFs had reduced
proliferative potential. To investigate this defect further,
flow cytometry was used to determine the population of
cells in different stages of the cell cycle (Figure S3). While
16.9% of the wild-type MEF population was in G2/M,
25.9% of the dp heterozygous MEF population was in
G2/M. Consistent with the inability of dp heterozygous
MEFs to proliferate, these cells expressed senescence-
associated b-galactosidase (SA-b-gal) activity, a marker
of senescent cells (Figure 2B) (Dimri et al., 1995). Whereas
very few senescent cells were detected in early passage
wild-type or df heterozygous cultures, a significant in-
crease in the number of senescent cells was present in
dp heterozygous cultures (Figure S4). These analyses indi-
cate that duplication of D4Mit190-51 dramatically com-
promises proliferation and enhances cellular senescence.
dfHeterozygous MEFs Have Enhanced Proliferation,
Immortalize, and Form Foci Spontaneously
We found that df heterozygous MEFs had significantly
enhanced proliferation compared to wild-type cells
(Figure 2A). Flow cytometry indicated that, while 16.9%
of the wild-type MEF population was in G2/M, only
11.9%of the df heterozygous population was in this phase
of the cell cycle (Figure S3).
Whereas wild-type and dp heterozygous MEFs could
only be serially passaged eight to ten times, df heterozy-
gous MEFs could be passaged extensively (i.e., 48 times
to date), indicating that immortalized cells are easily se-
lected for in the df heterozygous culture (Figure 2C, left).
To determine if loss of the wild-type allele accompanies
immortalization, we used simple sequence length poly-
morphism (SSLP) PCR (Figure 2C, right). Both wild-type
and df alleles were detectable in early passage MEFs
from F1 df heterozygous embryos, as was also the case
with immortalized df heterozygous cells at passage 37.
When cells were grown at high density to assess
contact inhibition, wild-type cells formed monolayers,
whereas df heterozygous cells formed foci with a fre-
quency of approximately 105 (Figure 2D). These findings(D) Gene targeting in the st clone shown in (A) was performed tomodify endpointD4Mit51 to yield doubly targeted (dt) clones. Only the Trans-targeting
event (in which both targeting events occur on different homologs) is shown here (cis events are depicted in Figure S2). The loxP site, a puromycin
resistance cassette (P), the 30 half of the hprt locus (30 ), and an Agouti transgene (Ag) were integrated at theD4Mit51 locus (upper). Accurate targeting
of puromycin-resistant (PR) clones was assessed by Southern analysis of SpeI (Sp)-digested DNA by using the 1.3 kb SacI gap probe; a 5.2 kb frag-
ment is diagnostic for dt clones (lower).
(E) Cre-mediated recombination. trans-targeted dt clones generated hypoxanthine aminopterin thymidine (HAT)-resistant (HR), GR, PR df/dp clones.
(F) PCR of late-stage embryos from df/dp X wild-type matings identifies wild-type (lanes 1 and 6), df heterozygous (lanes 4, 5, and 7), and dp hetero-
zygous (lanes 2 and 3) progeny. M, l BstEI marker; d, water control. Drug resistance gained in a particular step is underlined.Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 461
Figure 2. Phenotype of df Heterozygous and dp Heterozygous MEFs
(A) Proliferation assay in wild-type (black), dp heterozygous (blue), and df heterozygous (red) MEFs. Error bars are shown.
(B) Senescence assay of passage 4 MEFs (for quantitation, see Figure S4). Scale bar, 0.2 mm.462 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.
indicate that heterozygosity of D4Mit190-51 leads to en-
hanced proliferation, sensitivity to immortalization, and
spontaneous foci formation.
Deletion of D4Mit190-51 Causes Hyperproliferation,
whereas Duplication of This Region Causes
Apoptosis In Vivo
df heterozygous mice were grossly normal and indistin-
guishable from wild-type progeny at E17.5; however, df
heterozygous adult mice frequently developed hyperpla-
sia in a variety of tissues (Table S2). In contrast, late
gestation dp heterozygous embryos had striking develop-
mental abnormalities (exencephaly, eye defects [micro-
phthalmia], a conspicuous curling of the tail) that caused
them to die perinatally (Figure S5A). Histological analysis
revealed that the neural tube contained a large number
of cells that appeared apoptotic (Figure S5B). Indeed,
TUNEL assays on sagittal sections detected a marked
increase in the number of apoptotic cells in tissues of dp
heterozygous embryos, which was particularly notable in
the neural tube (Figure 3A). This analysis indicates that
deletion and duplication of D4Mit190-51 causes hyper-
proliferation and apoptosis, respectively, providing in
vivo evidence that this region is a potent regulator of
cellular proliferation and survival.
The dp Heterozygous Phenotype Is Caused
by Enhanced Gene Dosage
To test the hypothesis that the excessive apoptosis of dp
heterozygous mice was caused by enhanced dosage of
the D4Mit190-51 interval, we evaluated the phenotype of
E17.5 df/dp embryos (Figure 3B). dp heterozygous em-
bryos had striking developmental defects, as shown
above. df/df embryos were not obtained in these crosses,
suggesting that D4Mit190-51 homozygosity is embryonic
lethal. Importantly, df/dp embryos were indistinguishable
from wild-type controls, demonstrating that the df allele
functionally rescues the developmental defects character-
istic of dp heterozygous embryos. In addition, df/dp mice
(n = 11) obtained from df/dp intercrosses were viable and
fertile (Figure 3B, lower left). Furthermore, proliferation of
df/dpMEFs was essentially equivalent to that of wild-type
MEFs (Figure 3C). These analyses provide direct genetic
evidence thatboth theenhancedapoptosis ofdpheterozy-
gous mice in vivo and the reduced proliferation of dp het-
erozygous MEFs in culture are due to increased dosage
of D4Mit190-51. Therefore, proliferation, apoptosis, and
senescence are tightly regulated by dosage of this region.
The dp Heterozygous Phenotype Is p53 Dependent
To examine whether the phenotype of dp heterozygous
cells was p53 dependent, we used a short hairpin RNA(shRNA) specific for p53 to knock down p53 in dp hetero-
zygous MEFs (Figure 4A). Whereas control (GFP-infected)
dp heterozygous cultures proliferated poorly, dp hetero-
zygous cultures expressing a p53 shRNA proliferated
robustly.
We next asked whether p53 deficiency could protect dp
heterozygousmice from apoptosis in vivo and rescue their
perinatal lethality. Progeny from df/dp and p53+/ inter-
crosses produced viable dp heterozygous; p53+/ new-
borns with developmental defects, but these defects were
significantly less severe than those of dp heterozygous
mice (Figure 4B), indicating that p53 heterozygosity par-
tially rescues the apoptotic phenotype. Although many
of these mice became runted, developed ataxia, and did
not survive until weaning, some dp heterozygous; p53+/
mice survived to adulthood. Subsequent df/dp; p53+/ X
p53+/ crosses produced viable, fertile dp heterozygous;
p53/ progeny (Figure 4B, lower). These analyses pro-
vide direct genetic evidence that both the proliferative
and apoptotic defects of dp heterozygous cells are res-
cued by p53 deficiency, indicating that increased dosage
of D4Mit190-51modulates proliferation, senescence, and
apoptosis in a p53-dependent manner.
p53 Is Compromised in df Heterozygous Cells
An important advantage of chromosome engineering is
that the phenotype caused by gain and loss of the same
genomic region can be directly compared and contrasted.
Since increased dosage of D4Mit190-51 enhances p53
function, we reasoned that reduced dosage of this region
should lead to compromised p53 function. Although real-
time PCR revealed that p53 expression at the transcript
level was essentially equivalent in wild-type and df hetero-
zygous MEFs, western analysis revealed that basal p53
expression at the protein level was compromised in df het-
erozygous cells (Figure 4C). Accordingly, expression of
the p53 target genes p21 and Mdm-2 was reduced in df
heterozygous MEFs (Figure 4C, left). To investigate if df
heterozygous cells could induce p53 in response to DNA
damage, MEFs were treated with adriamycin and p53 ex-
pression assessed by western analysis (Figure 4C, right).
df heterozygous cells were able to induce p53 as effi-
ciently as wild-type cells. However, p53 levels began to
decline in df heterozygous cells 24 hr following DNA
damage. To extend these findings, we analyzed df hetero-
zygous, wild-type, and dp heterozygous MEFs for p53
expression by immunofluorescence and found a direct
correlation between dosage and p53 expression
(Figure 4D). These analyses revealed that p53 expression
was compromised and enhanced in df heterozygous and
dp heterozygous cells, respectively, demonstrating that
D4Mit190-51 positively regulates p53.(C) Immortalization assay (left) and PCR (right) using SSLP primers specific for the df allele (df), primers that differentiate between the wild-type (B6
mouse strain) and the df (129Svmouse strain) alleles (D4Mit308), and control primers (actin). DNA from the 129Sv strain (lane 2), the B6 strain (lane 3),
F1 (B6, 129Sv) dp heterozygous mice (lane 4), and passage 37 (i.e., immortalized) dp heterozygous cells from F1 mice (lane 5); water control (lane 1).
Error bars are shown.
(D) Focus formation assay.Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 463
Figure 3. Reducing Dosage of D4Mit190-51 Rescues the dp Heterozygous Phenotype
(A) TUNEL assay.
(B) Whole-mount analysis (upper) and genotyping by PCR (lower left) of E17.5 embryos from df/dp X df heterozygous matings. Lane 1, negative con-
trol; lane 2, wild-type; lane 3, df heterozygous; lanes 4 and 5, dp heterozygous; lane 6, df/dp. df/dpmice are viable and fertile as adults (lower right).
(C) Proliferation of dp heterozygous and df/dp MEFs. Error bars are shown.464 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.
Identification of the Proliferation-Suppressing
Gene Mapping to D4Mit190-51
D4Mit190-51 includes 52 annotated genes (see Figure 1B
and Table S1). Reasoning that increased dosage of a sin-
gle gene within this region modulates proliferation, we
screened for genes that would functionally rescue the pro-
liferation defect of dp heterozygous cells when depleted.
Proof of principal experiments for this screen were that
the proliferation defect of dp heterozygous MEFs could
be rescued by the df allele as well as by shRNA-mediated
knockdown of p53 (see Figures 3B and 4A), indicating that
reducing dosage of D4Mit190-51 restores proliferation
and that RNAi is effective in dp heterozygous MEFs.
To prioritize between candidate genes, we assessed
the Gene Ontology (GO) terms and selected a number of
candidates (see Table S1). Retroviral constructs encoding
shRNAs specific for Camta1, Chd5, Dffb, Dnajc, Errfi1,
Hes2, Hkr3a, Kcnabb, p73, Per3, Prdm16 were generated
(Table S3) and constructs were tested for their ability to
knock down their targets in wild-type cells by real-time
PCR (Figure 5A; data not shown). Next, a number of these
hairpins were scored for their ability to bypass the prolifer-
ation defect of dp heterozygous cells (Figure 5B; data
not shown). dp heterozygous MEFs infected with shRNA
constructs specific for Kcnabb, Camta1, or Dnajc prolifer-
ated poorly and were indistinguishable from those in-
fected with the GFP control (Figure 5B; data not shown).
dp heterozygousMEFs expressing p73 shRNA constructs
proliferated even more poorly than dp heterozygous
GFP controls, indicating that p73 deficiency exacerbated
rather than rescued the dp heterozygous phenotype
(Figure S6; A.B. and A.A.M., unpublished data). In con-
trast, two distinct shRNA constructs specific for the
chromodomain helicase DNA binding protein 5 (Chd5)
efficiently rescued the proliferative defect of dp heterozy-
gous MEFs (Figure 5B). Importantly, the extent of knock-
down correlated well with the efficiency of rescue. The
most efficient Chd5 hairpin, shChd5-2, restored pro-
liferation of dp heterozygous cells nearly as well as, but
subsequent to, p53 knockdown (data not shown). This
suggests that p53 is genetically downstream of Chd5,
consistent with the ability of p53 deficiency to rescue the
phenotype of dp heterozygous cells in culture and in vivo,
respectively.
The ability of Chd5 knockdown to restore proliferation
in dp heterozygous cells indicates that enhanced dosage
of Chd5 suppresses proliferation of dp heterozygous
MEFs. We also tested whether knockdown of Chd5
could enhance proliferation in wild-type primary cells
(Figure S7). As was found with dp heterozygous MEFs,
wild-type cells in which Dnajcwas knocked down prolifer-
ated similarly to GFP-infected cells. In contrast, Chd5
knockdown enhanced proliferation of wild-type MEFs,
as was also the case when p53 was knocked down in
wild-type cells (Figure S8). These results indicate that
Chd5 is the genewithin theD4Mit190-51 interval encoding
a negative regulator of proliferation that induces potent
tumor-suppressive mechanisms.Chd5 Positively Regulates p53-Mediated Pathways
We next tested whether wild-type cells in which Chd5 was
specifically depleted by using RNAi phenocopy df hetero-
zygous cells in their inability to modulate p53 (Figure 5C;
data not shown). Expression of Chd5 was reduced in
both df heterozygous MEFs and in wild-type cells in which
Chd5 was knocked down. Both df heterozygous and
wild-type shChd5MEFs expressed p53 transcript at levels
that were essentially equivalent to that of wild-type GFP
cells, whereas RNAi-mediated knockdown of depleted
p53 expression and compromised expression of the p53
target genes p21, Mdm-2, PUMA, Bax, and PML.
Whereas wild-typeGFPMEFs expressed these p53 target
genes robustly, expression was significantly reduced in
both df heterozygous and wild-type shChd5-2 MEFs. Im-
portantly, p53 transactivation in wild-type MEFs in which
Chd5 was knocked down paralleled that of df heterozy-
gous cells, indicating that Chd5 is the gene within the
D4Mit190-51 interval that modulates p53. These analyses
demonstrate that p53 is compromised when Chd5 is
depleted, indicating that Chd5 positively regulates p53-
mediated pathways.
Chd5 Suppresses Transformation
Since p53 deficient cells are susceptible to oncogenic
transformation and both engineered heterozygosity of
D4Mit190-51 and specific knockdown of Chd5 compro-
mise p53 function, we assessed if oncogenic Ras could
transform Chd5-compromised cells. First, wild-type
GFP, wild-type shDnajc, wild-type shp53, df heterozy-
gous, and wild-type shChd5-2 cells were infected with
retrovirus expressing RasV12 and the proliferation pheno-
type analyzed (Figure 6A). Whereas wild-type GFP MEFs
expressing oncogenic Ras became senescent, wild-type
cells in which p53 had been knocked down proliferated
robustly in response to Ras. Importantly, Ras induced
robust proliferation both in df heterozygous MEFs and in
wild-type MEFs in which Chd5 had been knocked down.
Ras induced proliferation more effectively in cells in which
Chd5was knocked down as compared to df heterozygous
cells, suggesting that RNAi reduced Chd5 levels more ex-
tensively than that achieved by engineered heterozygosity
of Chd5.
To determine if Ras could transform Chd5-compro-
mised cells, colony assays were performed in Ras-ex-
pressing cells (Figure S9). Both df heterozygous and p53
knockdown cells were readily transformed by oncogenic
Ras, whereas Ras was not able to transform wild-type
GFP cells (Figure S9A). Furthermore, specific knockdown
of Chd5 rendered wild-type MEFs susceptible to transfor-
mation (Figure S9B). We extended this finding by assess-
ing anchorage-independent growth of Ras-expressing
cells in soft agar (Figure 6B). Whereas wild-type GFP
MEFs expressing oncogenic Ras were incapable of form-
ing foci in this assay, both df heterozygous and wild-type
shChd5-2 MEFs that expressed Ras readily formed foci.
These analyses indicate that heterozygous deficiency of
D4Mit190-51 and specific knockdown of Chd5 sensitizeCell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 465
Figure 4. Dosage of D4Mit190-51 Directly Correlates with p53 Function
(A) RNAi-mediated knockdown of p53. dp heterozygousMEFs infected with a retroviral construct expressing either GFP or shp53 (left) were assayed
for proliferation (right). Error bars are shown.466 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.
cells to oncogenic transformation, indicating that Chd5
protects against malignant transformation.
Chd5 Modulates p16Ink4a/p19Arf
To investigate the mechanism whereby Chd5 regulates
p53 and suppresses Ras-mediated transformation, we
tested if df heterozygous and Chd5 knockdown cells
were impaired in their ability to modulate pathways up-
stream of p53. Since oncogene-induced pathways that
regulate p53 were perturbed by either heterozygosity of
the D4Mit190-51 interval or by deficiency of Chd5, we
focused on identifying perturbations in the oncogene-
induced pathways that have implicated Ink4/Arf—a locus
that encodes the cyclin-dependent kinase inhibitor
p16Ink4a and p19Arf.
Whereas p16Ink4a and p19Arf were induced at the tran-
script level in p53-deficient cells and Ras enhanced this
effect, their expression was significantly compromised in
both df heterozygous and in Chd5 knockdown cells,
both prior to and following Ras expression (Figure 6C,
left). Although p19Arf expression was induced to levels
equivalent to that of wild-type cells at the transcript level,
p16Ink4a expression remained compromised in Chd5-
deficient cells.
Western analyses in Ras-expressing cells indicated that
whereas Ras induced expression of both p16Ink4a and
p19Arf in wild-type GFP cells, and expression of p19Arf in
response to Ras was even more robust in MEFs in which
p53 had been knocked down, as reported previously
(Lowe and Sherr, 2003), expression of p19Arf in Ras-ex-
pressing df heterozygous MEFs was severely diminished
(Figure 6C, middle). Importantly, specific knockdown of
Chd5 caused a compromise in Ras-mediated induction
of p19Arf that closely paralleled that of df heterozygous
cells. Ras-mediated induction of p16Ink4a was also sub-
stantially reduced at the protein level in response to Ras
both in cells heterozygous for the D4Mit190-51 deletion
and in cells rendered deficient for Chd5 by RNAi-mediated
knockdown. To extend these findings, we analyzed df het-
erozygous, wild-type, and dp heterozygous MEFs for
p19Arf and p16Ink4a expression by immunofluorescence
(Figure 6C, right). This analysis revealed that expression
of both p19Arf and p16Ink4a was compromised and en-
hanced in df heterozygous and dp heterozygous cells, re-
spectively, supporting the finding that Chd5 positively reg-
ulates the Ink4/Arf locus.
To functionally validate the hypothesis that Chd5 mod-
ulates proliferation by facilitating p19Arf, we used RNAi to
deplete p19Arf in dp heterozygous MEFs (Figure 6D). Re-markably, knockdown of p19Arf bypassed the proliferation
defect of dp heterozygous cells, and proliferation assays
revealed that dp heterozygous MEFs in which p19Arf was
knocked down proliferated more efficiently than GFP-in-
fected control cells (p = 0.005) and achieved proliferation
levels comparable to that of Chd5 knockdown (p = 0.435).
In contrast, knockdown of p16Ink4a caused dp heterozy-
gous cells to proliferate only slightly better than controls
(p = 0.15). These analyses provide functional evidence
that p19Arf is maintained by a gene within the D4Mit190-
51 interval. This supports the notion that Chd5 maintains
p53 levels by facilitating expression of p19Arf and that de-
ficiency of Chd5 predisposes to malignant transformation
by compromising the p19Arf/p53 pathway.
Chd5 Is a Tumor Suppressor Gene
Consistent with the above findings suggesting that Chd5 is
a potent tumor suppressor, we found that df heterozygous
mice are prone to spontaneous tumors (Figure 6E; Table
S2). Squamous cell carcinoma, lymphoma, and hiber-
noma (a mesenchymal neoplasm) have been found in
the df heterozygous cohort. This neoplasm provides evi-
dence that the MEF phenotypes described in this study
are relevant to tumorigenisis in an in vivo setting. Chd5 is
expressed in cells that form tumors when 1p36 is deleted
as well as in cell types that give rise to the tumors we ob-
served in df heterozygous mice (Figure S10). To examine
if tumors from df heterozygous mice retain the wild-type
allele, genomic DNA was subjected to Southern analysis
(Figure 6E, right). This analysis demonstrated that the
wild-type chromosome is retained in this tumor. Together,
these findings indicate that heterozygosity ofD4Mit190-51
predisposes to malignancy in vivo.
To demonstrate that Chd5 is a tumor suppressor, we
asked whether Chd5 deficiency predisposes to tumori-
genesis in vivo in athymic nude mice. Control MEFs
(wild-type GFP and wild-type shDnajc) failed to form tu-
mors (0 neoplasms/10 injections), whereas p53 knock-
down MEFs formed robust tumors (10 neoplasms/10
injections) (data not shown). In contrast, both df heterozy-
gous cells and wild-type MEFs in which Chd5 was specif-
ically knocked down formed tumors readily (20 neo-
plasms/20 injections and 11 neoplasms/12 injections,
respectively) (Figure 6F). These studies conclusively dem-
onstrate that Chd5 functions as a tumor suppressor.
CHD5 Is Deleted in Human Tumors
After having shown that Chd5 is a tumor suppressor in
mice, we asked if CHD5 functions in human cancer by(B) p53 deficiency in vivo. Litters including dp heterozygous; p53+/ (black asterisks) and corresponding Southern analysis (upper right). dp hetero-
zygous; p53/ mice (lower left; red asterisks) were identified by PCR (lower right). Southern, lanes 1 and 2, wild-type; lanes 3–5, p53+/; lane 6, dp
heterozygous; p53+/. Endogenous (E), targeted (T) p53 alleles are shown, as well as the p53 pseudogene (P). PCR, lane 1, dp heterozygous; p53/;
lane 2, p53/; lane 3, wild-type; lane 4, p53+/. Wild-type (WT) and inactivated (mt) p53 alleles are shown.
(C) p53 expression in df heterozygous cells. p53 expression and transcriptional activation of p53 target genes was evaluated by real-time PCR (left)
and by western analysis in wild-type and df heterozygous cells prior to and following adriamycin treatment (right). Scale bars are shown. Long (upper)
and short (middle) exposures; actin (lower).
(D) p53 expression by immunofluorescence (scale bar, 20 mm).Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 467
Figure 5. RNAi-Mediated Knockdown Identifies Chd5 as the D4Mit190-51 Proliferation-Suppressing Gene
(A) Knockdown of target genes in wild-type MEFs assessed by real-time PCR. GFP-expressing cells serve as reference. Error bars are shown.
(B) Knockdown of Chd5 using two different short hairpins (shChd5-2 and shChd5-4), and knockdown of Kcnabb or Dnajc. The phenotype of cells
3 days after infection (left) and proliferation 5 days after infection (right) are shown.
(C) Expression of Chd5, p53, and the p53 target genes p21 and Mdm-2 assessed by real-time PCR. Error bars are shown.analyzing expression of genes mapping to chromosome
1p in a panel of 54 human gliomas (Bredel et al., 2005b)
(Figure 7A). CGHPRO data analysis tools (Chen et al.,
2005) and a circular binary segmentation algorithm
(Olshen et al., 2004) were used to define deletions. This
analysis mapped CHD5 to a 5.4 Mb minimal common de-468 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.letion region (MCR) between 1p36.32 and 1p36.22. The
corresponding gene expression portraits (Bredel et al.,
2005a) were used to compare CHD5 expression in normal
human brain and in tumors with or without CHD5 deletion
(Figure 7B). Whereas nondeleted tumors expressed
CHD5 at levels comparable to normal brain (p = 0.66,
independent t test), tumors with deletion had a significant
decrease in CHD5 expression (p = 0.00006) (Figure 7B).
The narrow range of CHD5 expression in deleted tumors
contrasts markedly with the much wider range in tumors
without deletion. To assess if there is a significant associ-
ation between gene dosage and CHD5 expression in the
tumors, we used an integrative strategy that combines
a modification of signal-to-noise ratio computation and
permutation testing (Juric et al., 2007) in deleted versus
morphology-matched nondeleted tumors. The measure
of statistical significance in terms of the false discovery
rate (the q value) (Storey and Tibshirani, 2003) discloses
significance for the genetic level in driving expression
levels of CHD5 in the tumors (q < 0.05). These findings
are consistent with our studies that identify Chd5 as a
tumor suppressor and pinpoint deletion of the 1p36
interval encompassing CHD5 as an initiating event in
tumorigenesis.
DISCUSSION
Rearrangements of 1p were first discovered in 1977
(Brodeur et al., 1977). Since then, 1p36 deletions have
been shown to be common in end-stage tumors of epithe-
lial, neural, and hematopoietic origin (Bello et al., 1995;
Bieche et al., 1993;Moley et al., 1992;Mori et al., 1998; Po-
etsch et al., 2003; Praml et al., 1995; White et al., 1995;
White et al., 2005). Despite extensive efforts, this gene
had not been identified. We predicted that deletions en-
compassing a potent tumor suppressor locus would com-
promise tumor-suppressive mechanisms and predispose
to cancer, thereby functionally pinpointing novel tumor
suppressors to a defined region of the genome. In addition
to generating loss-of-function models, the chromosome-
engineering approach produced gain-of-function models,
allowing us to directly compare the phenotype caused
by decreased and increased dosage, respectively.
This work has several major findings. First, we identify
the D4Mit190-51 region as a potent regulator of prolifera-
tion, senescence, and apoptosis. We found an inverse
correlation between dosage of this region and cellular
proliferation. While increased dosage triggers the tumor-
suppressive mechanisms of cellular senescence and apo-
ptosis, decreased dosage of the same region enhances
immortalization, increases spontaneous foci formation,
and renders cells sensitive to oncogenic transformation.
Second, we demonstrate thatD4Mit190-51 positively reg-
ulates p53 via p19Arf. We found that the enhanced senes-
cence and apoptosis caused by increased dosage of the
D4Mit190-51 region is p53 dependent, both in cultured
cells and in vivo, demonstrating that p53 function is exac-
erbated by increased dosage of this region. On the other
hand, p53 function is severely compromised by hetero-
zygosity of D4Mit190-51, thereby facilitating oncogenic
transformation in cultured cells and predisposing to spon-
taneous tumorigenesis in vivo. We demonstrate that
D4Mit190-51 deficiency cripples both basal- and onco-
gene-induced expression of p16Ink4a/p19Arf, suggestinga mechanism for both compromised p53 function and
susceptibility to transformation. Third, we identify Chd5
as the gene within D4Mit190-51 that regulates prolifera-
tion and mediates tumor-suppressive mechanisms. In-
deed, depletion of Chd5 rescues the proliferative defect
of cells with increased dosage of D4Mit190-51, indicating
that enhanced expression of Chd5 alone is responsible for
the proliferative defect of these cells. Importantly, knock-
down of Chd5 in wild-type cells phenocopies cells with an
engineered deletion of D4Mit190-51 with regards to
enhanced proliferation; sensitivity to oncogenic trans-
formation; compromised expression of p16Ink4a, p19Arf,
and p53; and ultimately tumorigenesis. Fourth, we map
CHD5 to anMCR in human tumors and uncover a frequent
correlation between deletion of this region and reduced
CHD5 expression. These findings (Figure 8) functionally
identify CHD5 as a novel tumor suppressor mapping to
human 1p36.
Chd5 is a member of the chromodomain superfamily
that consists of a large number of proteins with chromatin
organizingmodulator (chromo) domains (Thompson et al.,
2003). In mammals, this superfamily can be subdivided
into five families based on the presence of specific protein
motifs that endow each family of proteins with unique
function (Jones et al., 2000). For example, the Pc-G
family—first identified as the human homolog of Drosoph-
ila Polycomb (Pc), a transcriptional repressor of homeotic
genes—contains a Pc box, whereas the Chd family is
characterized by the presence of SWI/SNF-type heli-
case/ATPase- and DNA binding domains.
The Chd family is further subdivided into subfamilies
based on the absence (Chd1/2) or the presence (Chd3/
4/5) of two Zn binding plant homeodomain (PHD) fingers.
The PHD finger of the nucleosome-remodeling factor
NURF was recently reported as a domain that interacts
with H3K4-trimethylated histones—a mark of transcrip-
tionally active chromatin, suggesting that this domain fa-
cilitates transcriptional activation (Wysocka et al., 2006).
Thus, Chd proteins such as Chd5 possess a unique com-
bination of chromo, helicase, and DNA binding motifs.
This suggests that Chd5 may function similarly to other
chromodomain proteins that epigenetically modify chro-
matin to regulate gene expression networks affecting
development, stem cell fate, and cancer (Valk-Lingbeek
et al., 2004).
Identifying Chd5 as a tumor suppressor functionally val-
idates and extends the idea that chromatin remodeling
proteins function in cancer. How might a chromatin re-
modeling protein such as Chd5 modulate tumor suppres-
sion? In exploring the mechanism whereby Chd5 modu-
lates p53, we discovered that p19Arf, an upstream
inducer of p53 that is activated by oncogene-induced
pathways (Lowe and Sherr, 2003), is severely compro-
mised by Chd5 deficiency. Since p19Arf sequesters
Mdm2, a negative regulator of p53, Chd5 deficiency com-
promises p53 and facilitates tumorigenesis.
p19Arf and p16Ink4a are encoded by Ink4/Arf, one of the
most commonly inactivated loci in human cancer (EstellerCell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 469
Figure 6. Chd5 Functions as a Tumor Suppressor
(A) MEFs infected with RasV12-expressing retrovirus and the phenotype (left) and proliferation (right) analyzed. Error bars are shown.
(B) Transformation was assessed by anchorage-independent growth in soft agar by assessing morphology (left) and quantitating colony number
(right) (scale bar, 0.2 mm).470 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.
et al., 2001). p16Ink4a facilitates Rb- whereas p19Arf stimu-
lates p53-mediated tumor-suppressive pathways. Acti-
vated oncogenes induce expression of both p19Arf and
p16Ink4a, thereby protecting from malignancy (Serrano
et al., 1997). Importantly, Ink4/Arf is transcriptionally si-
lenced by several Pc-G proteins such as Bmi-1, Cbx7,
Ring1b, and Ezh2 (Gonzalez and Serrano, 2006).
We found that p19Arf expression at both transcript and
protein level is compromised in Chd5-deficient cells. The
inability of Ras to induce expression of p19Arf that is pro-
portional to the extent of p53 deficiency indicates that
Ink4/Arf is inaccessible in Chd5-compromised cells, an
idea supported by the finding that expression of p16Ink4a
is also severely diminished by Chd5 deficiency. These
findings support a model in which the chromatin-remodel-
ing activity of Chd5 is required for appropriate transcrip-
tional activation of Ink4/Arf.
Chd5’s role as a tumor suppressor is consistent with our
finding that CHD5 maps within an MCR in human cancer.
Our findings are in line with previous studies that have re-
ported 1p36 deletions in human cancer that include
CHD5 (Bello et al., 1995; Bieche et al., 1993; Moley et al.,
1992; Praml et al., 1995; White et al., 1995; White et al.,
2005). Several studies have identified relatively small dele-
tions that include CHD5 and found reduced expression of
CHD5 and other candidate genes in tumor cell lines (Law
et al., 2005; Thompson et al., 2003; White et al., 2005).
Our analyses revealing that Chd5 is a potent tumor sup-
pressor functionally validate the hypothesis that deletions
of 1p36 initiate tumorigenesis. Furthermore, our finding
that Chd5 deficiency cooperates with activated Ras is in
line with the observation that deletion of CHD5 and ampli-
fication of NMYC are genetically linked (Thompson et al.,
2003). Although Chd5 appears to be the sole tumor sup-
pressor within the D4Mit190-51 interval, our studies do
not exclude the possibility that additional tumor suppres-
sor genes corresponding to human 1p36 mapping to re-
gions flanking the D4Mit190-51 region exist. Loss of het-
erozygosity studies identified deletions that map outside
the D4Mit190-51 region (Mori et al., 1998; Poetsch et al.,
2003). Whether or not these flanking deletions also initiate
tumorigenesis awaits functional studies such as the ones
described in this report.
We found that heterozygosity of Chd5 predisposes to
malignancy and that the wild-type locus appears to be
retained in immortalized cells as well as in spontaneous
tumors. Retention Chd5 suggests a mechanism that devi-ates from Knudsen’s two-hit hypothesis (Knudsen, 1971).
Indeed, analysis of neuroblastoma cell lines with 1p dele-
tions identified only a single missense mutation within
Chd5, consistent with the hypothesis that complete inac-
tivation of Chd5 by mutation is not a prerequisite for tu-
morigenesis (Thompson et al., 2003). This could explain
why studies that used loss of expression as the criterion
for validating tumor-suppressive function may have
missed CHD5 as a likely candidate.
Identification of Chd5 as a tumor suppressor is the first
demonstration, to our knowledge, that a member of the
Chd family of chromatin-remodeling proteins functions in
tumorigenesis. Other members of the chromodomain su-
perfamily, however, have well-established roles in cancer.
Bmi-1, for example, is an oncogene that cooperates with
activated Ras to transcriptionally repress Ink4/Arf (Jacobs
et al., 1999). Thus, the Ink4/Arf locus appears to be a com-
mon target for epigenetic modulation by diverse chromo-
domain-containing proteins.
Pc-G members such as Bmi-1 have been implicated as
transcriptional repressors, and Pc specifically recognizes
H3K27-trimethylated histones, a mark of silenced chro-
matin (Cao et al., 2002; Muller et al., 2002). In contrast,
Chd1 specifically interacts with H3K4-trimethylated his-
tones, marks of transcriptionally active chromatin (Flana-
gan et al., 2005; Pray-Grant et al., 2005). Although both
Chd1 and Chd5 are distant members of the Chd family,
they share the SWI/SNF-helicase motif, which can facili-
tate gene activation (Jones et al., 2000). Pc, on the other
hand, represses transcription by recruiting chromatin-
remodeling proteins that make the chromatin inaccessible
to SWI/SNF-helicase/ATPase activity. Whether or not
antagonism between Pc-G and Chd proteins exists has
not been explored. We propose a model in which Chd5
maintains chromatin in a transcriptionally active state
that facilitates expression of p16Ink4a and p19Arf, thus pro-
viding tumor suppression.
Although we have focused on the p19Arf/p53 arm of the
Chd5-mediated pathway, we demonstrate that expres-
sion of p16Ink4a is also reduced in Chd5-deficient cells,
raising the possibility that p16Ink4a/Rb-mediated path-
ways are also compromised by Chd5 deficiency. Although
further investigation of this hypothesis is warranted by
using the models described herein, it is intriguing that
the first tumor found in df heterozygous mice was an
SCC of the skin, a tumor that rarely develops in p53-
compromised mice (Donehower et al., 1992), suggesting(C) Expression of p53, p16Ink4a, and p19Arf are compromised in both df heterozygous and wild-type shChd5-2MEFs. Real-time PCR prior to (upper)
and following (lower) expression of Ras was used to evaluate expression of p16Ink4a and p19Arf. Western analysis in Ras-infected cells was used to
assess expression of Ras, p53, p16Ink4a, and p19Arf; actin was used as a loading control. For p19Arf, S and L denote short and long exposures, re-
spectively. Expression of p16Ink4a and p19Arf examined by immunoflourescence (scale bar, 20 mm for p16Ink4a, 10 mm for p19Arf).
(D) RNAi-mediated knockdown. Error bars are shown.
(E) Heterozygosity of D4Mit190-51 predisposes to spontaneous tumorigenesis. Histological analysis of squamous cell carcinoma (SCC) (left), lym-
phoma (middle), and hibernoma (right) from the df heterozygous cohort (scale bar, 10 mm). Southern analysis (far right) of the SCC is shown above.
Endogenous (E) and targeted (T, df) alleles are shown.
(F) Both df heterozygous MEFs and wild-type MEFs in which Chd5 has been specifically knocked down that express Ras form tumors with similar
kinetics in nudemice. A representative neoplasm is shown at the gross level (left). The underside of the skin reveals the extensive vasculature (middle,
scale bar, 2 mm), and histological analysis denotes the neoplastic pathology (right, scale bar, 10 mm).Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 471
Figure 7. CDH5 Is Deleted in Human Tumors
(A) High-resolution gene dosage profiles along chromosomal arm 1p. 1795 clones were analyzed by cDNA array-CGH (blue, gene dosage loss; red,
gene dosage gain). Frequent deletion of CHD5 (recurrence frequency, 17%, green arrows) within a 5.4 Mb MCR between 1p36.32 and 1p36.22.
(B) Corresponding CHD5 transcript abundance in normal brain, morphology matched tumor with (n = 6) or without (n = 12) CDH5 deletion assessed
versus universal human reference total RNA on the same genomics platform. Standard deviation is shown.that p19Arf/p53-independent pathways are compromised
by Chd5 deficiency. Whether or not Chd5 is required for
expression of p16Ink4a and p19Arf in diverse cell types,
and whether Chd5 maintains stem cells as has been
elegantly demonstrated for Bmi-1 (Bruggeman et al.,
2005), remains to be explored.
In summary, chromosome engineering has been invalu-
able for functionally identifying CHD5 as a tumor suppres-
sor mapping to 1p36. Chd5 deficiency predisposes to
malignancy by crippling tumor-suppressive pathways in-
volving p16Ink4a, p19Arf, and p53. The idea that this chro-
modomain protein epigenetically regulates the Ink4/Arf lo-
cus draws notable parallels, yet striking contrasts, with the472 Cell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc.function of members of the Pc-G family of chromodomain
proteins. This work defines a previously unrecognized role
for CHD5 in cancer. We propose that CHD5 facilitates
transcriptional programs that provide tumor suppression
and that compromised CHD5 provides a common under-
lying mechanism for initiating tumorigenesis in diverse
types of human cancer.
EXPERIMENTAL PROCEDURES
Chromosome Engineering
AB2.2 ES cells (129S5 strain) were electroporated with 25 mg of the
pTVD4Mit190 or pTVD4Mit51 insertion vectors, clones were selected
Figure 8. Model for Chd5 in Tumor Suppression
Normal cells (diploid for Chd5) maintain p53 by appropriate regulation of p19Arf (upper). Duplication of D4Mit190-51 increases dosage of Chd5 and
increases p53 via enhanced expression of p19Arf (middle), triggering the potent tumor-suppressive mechanisms of senescence and apoptosis. In
contrast, heterozygous deficiency of D4Mit190-51 or specific knockdown of Chd5 decreases dosage of Chd5, which compromises p53 function
by reducing expression of p19Arf (lower). This compromise in p53’s tumor-suppressive function predisposes to malignancy.in G418 (180 mg/ml) or puromycin (3 mg/ml) for 8–10 days, and tar-
geting was assessed by Southern. Doubly targeted clones were
electroporated with the Cre plasmid pOG231, and clones were se-
lected in HAT (0.1 mM sodium hypoxanthine, 0.2 uM aminopterin,
and 0.016 mM thymidine), released in HT (0.1 mM sodium hypoxan-
thine and 0.016 mM thymidine) for 48 hr, and HRGRPR df/dp clones
identified.
Mouse Strains
df/dp clones were established as mouse strains, and F1 progeny from
chimera X C57BL/6J crosses were genotyped by PCR or Southern.
df/dp X p53+/ crosses were genotyped as described (Donehower
et al., 1992). PCR was performed with 10 ng genomic DNA using
a MasterCycler gradient thermocycler (Eppendorf) and reaction
products resolved on 2%–4% agarose gels. Primers are shown in
Table S4.
Cellular Assays
MEFswere generated and assessed for proliferation by plating 13 105
MEFs on 6-well dishes and harvesting and counting plates in triplicate
at 2 day intervals using a Z1 Coulter particle counter (Beckman-Coul-
ter). Immortalization was assessed by serially passaging 2 3 105 cells
every 3 days. Graphing and standard error were performed with Prism.
Cell cycle analysis was performed by flow cytometry using a BD LSRII
(BD Biosystems) and FACSDiVa (BD Biosystems). The SA-b-gal assay
was performed as previously described. Foci formation was per-
formed by growing cells at high density. Ras-infected cells were as-
sayed for transformation by staining colonies in crystal violet and by
anchorage-independent growth in 0.4% soft agar. Tumorigenesis as-
says in athymic nude mice were performed as described previously
(Hemann et al., 2004).Histological Analysis and TUNEL Assays
Tissues were harvested by using standard procedures and pathology
assessed by H.V. Unstained sections were analyzed for apoptosis us-
ing TUNEL (Amersham) according to the manufacturer’s protocol.
RNAi
shRNAs (see Table S3) were cloned in the MSCV-U6miR30-PIGDRI
(Dickins et al., 2005) with Ras or GFP (pMSCV-puro-PIG) (Hemann
et al., 2003). Retrovirus was produced by transfecting Phoenix cells
(G. Nolan, Stanford University) with shRNAs for 48 hr, the cells fed
with media (DMEM, 10% FBS, 1% penicillin/streptomycin), and
MEFs infected for 12 hr with viral supernatant and selected for 6–8
days. shRNA constructs for p53 and p16Ink4a have been described
previously (Dickins et al., 2005; Keyes et al., 2005).
Real-Time PCR
Total RNA was isolated with Trizol reagent (GIBCO), RT-PCR per-
formed on 0.5 mg total RNA using a Superscript first-strand cDNA syn-
thesis kit (Invitrogen), and real-time PCR performed using a Peltier
Thermal cycler (MJ Research) and a SYBRGreen PCR kit (Applied Bio-
systems). Samples were analyzed in triplicate, and expression was
compared to b-actin. Primers are shown in Table S4.
Western Analysis
MEFs were solubilized in Laemmli buffer and quantitated using a pro-
tein assay (Bio-Rad), and 10–20 mg protein was analyzed by using
standard procedures, with antibodies for specific for Ras (mouse
monoclonal, BD Transduction Laboratories, 1:500), p19 (Ab80, rabbit
polyclonal, Abcam, 1:1000), p16 (M156, rabbit polyclonal, Santa
Cruz, 1:500), p53 (CM5, Vector Laboratories, 1:500), and b-actin
(AC-15, mouse monoclonal, Sigma, 1:10000). Secondary antibodiesCell 128, 459–475, February 9, 2007 ª2007 Elsevier Inc. 473
were goat anti-mouse-HRP (IgG and IgM)- and goat anti-rabbit-HRP
(IgG; Pierce, 1:5000).
Supplemental Data
Supplemental Data include ten figures and four tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/3/459/DC1/.
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